

**Supplementary Table 1 Logistic regression analysis for predictors of respond in LAGC patients receiving NACI**

Variables	Univariate analyses		Multivariate analyses	
	HR (95% CI)	P value	HR (95% CI)	P value
Sex				
Female	1 [Reference]	NA		
Male	1.33 (0.28-6.33)	0.717		
Age				
<65	1 [Reference]	NA		
≥65	2.12 (0.43-10.52)	0.357		
Location				
lower third	1 [Reference]	NA		
middle third	3.20 (0.52-19.84)	0.211		
upper third	1.07 (0.15-7.82)	0.949		
cT				
cT3	1 [Reference]	NA		
cT4a	4.50 (0.34-60.15)	0.256		
cT4b	1.37 (0.23-8.30)	0.728		
cN				
cN1-2	1 [Reference]	NA		
cN3	2.00 (0.43-9.29)	0.376		
PD-L1 scores	0.92 (0.83-1.02)	0.098		
Tumor grade				
G1-2	1 [Reference]	NA		
G3	1.33 (0.28-6.33)	0.717		
Immunotherapy				
Nivolumab	1 [Reference]	NA		
Tislelizumab	2.00 (0.38-10.58)	0.415		
Others	2.00 (0.17-24.07)	0.585		
NLR				
High	1 [Reference]	NA		
Low	0.18 (0.02-1.71)	0.135		
Pre-NACI NET				
High	1 [Reference]	NA	1 [Reference]	NA
Low	0.13 (0.02-0.75)	0.023	0.13 (0.02-0.75)	0.023

Abbreviations: LAGC, locally advanced gastric cancer; NACI, neoadjuvant chemotherapy combined with immunotherapy; NET, neutrophil extracellular traps; G1-2, grade well and moderate; G3, grade poor; NLR, neutrophil-to-lymphocyte ratio.